Publications by authors named "P Loubet"

Introduction: In France, over 90% of people living with HIV-1 (PLWH) achieve virological suppression with effective combination of antiretroviral therapies (ART), but limited data exist on the motivation for switching ART.

Objective: To describe the reasons and determinants for switching ART, with a particular focus on doravirine-based regimens, in routine clinical practice in France.

Design: This analysis of cross-sectional baseline data is part of the DoraVIH study, a French, multicenter (15 sites), two-step observational cohort study that includes prospective follow-up for a subset of participants.

View Article and Find Full Text PDF
Article Synopsis
  • Bone and joint infections (BJIs) from multidrug-resistant bacteria, like carbapenem-resistant Enterobacterales, are rising, highlighting the need for new treatment options.
  • Novel β-lactam/β-lactamase inhibitors, specifically imipenem/cilastatin/relebactam (I-R) and meropenem/vaborbactam (MVB), lack sufficient data on their effectiveness for BJIs, particularly with prolonged infusions.
  • A case study showed successful treatment of vertebral osteomyelitis using extended and continuous infusions of I-R and MVB, suggesting these methods could be effective against BJIs caused by resistant bacteria.
View Article and Find Full Text PDF

Objective: To estimate the incidence of hospitalization with a diagnosis of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in France between 2013 and 2020, overall and stratified by age-group and immune status.

Methods: Retrospective observational, database study, using the French hospital discharge database, which includes private and public data for all day-care and inpatient stays. Adults aged ≥18 years, hospitalized between January 1, 2013, and December 31, 2020, with a diagnosis of HZ or PHN, were included.

View Article and Find Full Text PDF

Background: Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for hospitalized COVID-19 patients. Given the continued evolution of the disease, clinical management of COVID-19 relies on evidence from the current endemic period.

View Article and Find Full Text PDF